Strong dollar beats down pharma revenues

It's that time again: Earnings time. As you know, Johnson & Johnson and Abbott Laboratories reported earlier this week; today we have Baxter, Novartis, and Biogen Idec. So far it looks like a tough quarter for sales, with currency costs holding down revenues at some companies and new generic competition eating into others. Still, cost-cutting is helping to offset that revenue loss, with several drugmakers reporting better-than-expected profits. And some surprising sales growth for certain drugs has helped, too. Then there's also the confounding factor of low expectations, however; given the economic climate, analysts haven't been very bullish in predicting pharma earnings. Here's a sampling of the news:

  • Baxter International reported higher-than-expected net earnings of $587 million, or 96 cents per share, as improved margins helped outweigh the negative impact of foreign exchange rates. The company's bioscience unit performed best, sales-wise, with a 2 percent rise in sales despite currency effects; without the stronger dollar, those sales would have risen 13 percent.

  • Novartis boosted its drug-sales forecast, despite the fact that revenue growth was more than canceled out by conversion to dollars. Sales came in at 2 percent below the same period last year, or $10.5 billion. Profits fell by 10 percent to $2.04 billion. Nevertheless, CEO Daniel Vasella (photo) predicted "high single-digit" sales growth for the year, up from "mid-to-high" predicted earlier. Among the star products: the blood-pressure remedy Exforge and bone drug Reclast.

  • During its earnings call yesterday, Abbott Laboratories gave reporters a rundown on its plans for the Humira successor Simponi and touted the 20 percent increase in Humira sales to $1.3 billion. So far, Simponi has been capturing around 500 scrips per week, with 61,000 total weekly prescriptions in its drug class. So it has a long way to go, but Abbott execs called new competition "modest." We'll have to wait and see on that one.

  • Biogen Idec said second-quarter profit fell 30 percent to $144 million on research costs from its partnership with Acorda Therapeutics. The drugmaker beat analyst estimates, however, and boosted revenue to $1.1 billion on a 27 percent increase in sales of its big multiple sclerosis med Tysabri--despite the slow drumbeat of new cases of a potentially fatal brain infection among Tysabri patients.

There's plenty more numbers to come so stay tuned.

- get the Baxter news from Reuters
- read the Novartis results at Bloomberg
- find the Abbott analysis at the Wall Street Journal Health Blog
- see the Biogen story from Bloomberg

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.